Zepbound 'biggest lie': What the GLP-1 hype gets wrong

What did @seeinggrace actually say?

Not much, honestly. The transcript is almost entirely a rebuttal with no visible target. @seeinggrace says "I don't know where you got your information from" and insists that some unnamed claim is "incorrect," but the video never tells us what that claim is. We're working with a response without a question.

That's a real problem for fact-checking. The caption says "the biggest lie," which suggests something specific was said, likely in a comment, a stitch, or a previous video in a series. Without that context, we can evaluate the general territory of Zepbound misinformation rather than the specific claim. The community hashtags suggest this is aimed at a GLP-1 weight loss audience, so we can make reasonable guesses about what's likely being disputed.

Common targets in the Zepbound TikTok space include arguments about whether the drug causes muscle loss, whether results last after stopping, whether it's just "a crutch," or whether insurance covers it. Any of these could be "the biggest lie."

Does the science back this up?

That depends entirely on what the actual disputed claim was, which we don't have. What we do have is a body of trial data on tirzepatide, the active ingredient in Zepbound, and a clear picture of what's true and what isn't in this space.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide at 15mg produced a mean weight reduction of 20.9 percent over 72 weeks in adults with obesity. That's a real number from a rigorous randomized controlled trial. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide regained about two-thirds of their lost weight within a year. Both findings get distorted constantly online, either by people overselling permanence or by critics dismissing efficacy entirely.

If @seeinggrace was pushing back on either of those distortions, the science would likely side with them. If the claim was something else, we simply can't say.

What did they get wrong (or right)?

The video doesn't give us enough to evaluate specific accuracy. What it does give us is a confident, dismissive tone applied to an unknown claim. That's not inherently wrong, but it's a communication pattern worth flagging.

Confidence without transparency is a pattern that spreads misinformation even when the speaker is correct. If @seeinggrace has good information, the audience deserves to hear it, not just hear that someone else is wrong. Saying "that is incorrect" without explaining what's incorrect or why does almost nothing to move the needle on health literacy.

To be fair, TikTok's format often means context lives in comments or a series, and we may be missing that. If a previous video laid out the actual claim and evidence, this could be a reasonable follow-up. Without seeing that, we can credit the intent while noting the execution leaves the audience without actionable information. Reacting to misinformation is good. Giving people a reason to believe you is better.

What should you actually know?

If you're in the Zepbound community, here are the claims that circulate constantly and what the evidence actually says.

• "You'll gain it all back when you stop." Partially true. SURMOUNT-4 data shows significant regain after discontinuation, but not always complete regain, and ongoing use maintains results. This isn't unique to tirzepatide.
• "It destroys muscle." Oversimplified. Caloric restriction from any cause can reduce lean mass. Trials show that adding resistance training largely mitigates this. Tirzepatide itself is not uniquely muscle-wasting.
• "It's just a crutch and doesn't fix the real problem." This framing applies the same logic to insulin for diabetes and is not supported by current understanding of obesity as a chronic condition (Bray et al., 2017, Nature Reviews Disease Primers).
• "Compounded tirzepatide is the same as Zepbound." This is not established. Compounded versions are not FDA-approved and have not been tested for bioequivalence in clinical trials. They should not be treated as equivalent.

The bottom line is that tirzepatide has strong trial support, real limitations, and a lot of noise around it online. Anyone telling you something is wrong about it owes you a reason, not just a rebuttal.